CONTEXT: Real-world adherence to bisphosphonate therapy is poor. Consistent data support a relation between medication adherence and fracture reduction, but relatively little attention has been paid to the effect of the method used to measure adherence on this relation or on the relation between adherence and specific fracture types. OBJECTIVE: Our objective was to assess the relation between bisphosphonate adherence and the risk of hip, vertebral, distal forearm, and any fracture using different measures of adherence. DESIGN: We conducted a cohort study using administrative claims data. Adherence was assessed in sequential 60-d periods. In models incorporating time-varying measures of adherence, the adjusted relation between adherence and fracture was examined using several methods for calculating the proportion of days covered (PDC). PATIENTS: Patients included community-dwelling elderly enrolled in a Pennsylvania pharmaceutical assistance program and Medicare initiating an oral bisphosphonate for osteoporosis. MAIN OUTCOME MEASURES: Risk of hip, vertebral, distal forearm, and any osteoporotic fracture was assessed. RESULTS: Fractures occurred at a rate of 43 per 1000 person-years among the 19,987 patients meeting study eligibility criteria. There was an inverse relation between adherence and fracture rate for all adherence measures and fracture types, excluding distal forearm fractures. High (80-100%) cumulative PDC was associated with a 22% reduction in overall fracture rate, a 23% reduction in hip fracture rate, and 26% reduction in vertebral fracture rate. CONCLUSIONS: We found a consistent relation between adherence with osteoporosis treatment and fracture reduction, regardless of method for measuring PDC. The similarity in results across adherence measures is likely due to the high correlation between them.
CONTEXT: Real-world adherence to bisphosphonate therapy is poor. Consistent data support a relation between medication adherence and fracture reduction, but relatively little attention has been paid to the effect of the method used to measure adherence on this relation or on the relation between adherence and specific fracture types. OBJECTIVE: Our objective was to assess the relation between bisphosphonate adherence and the risk of hip, vertebral, distal forearm, and any fracture using different measures of adherence. DESIGN: We conducted a cohort study using administrative claims data. Adherence was assessed in sequential 60-d periods. In models incorporating time-varying measures of adherence, the adjusted relation between adherence and fracture was examined using several methods for calculating the proportion of days covered (PDC). PATIENTS: Patients included community-dwelling elderly enrolled in a Pennsylvania pharmaceutical assistance program and Medicare initiating an oral bisphosphonate for osteoporosis. MAIN OUTCOME MEASURES: Risk of hip, vertebral, distal forearm, and any osteoporotic fracture was assessed. RESULTS:Fractures occurred at a rate of 43 per 1000 person-years among the 19,987 patients meeting study eligibility criteria. There was an inverse relation between adherence and fracture rate for all adherence measures and fracture types, excluding distal forearm fractures. High (80-100%) cumulative PDC was associated with a 22% reduction in overall fracture rate, a 23% reduction in hip fracture rate, and 26% reduction in vertebral fracture rate. CONCLUSIONS: We found a consistent relation between adherence with osteoporosis treatment and fracture reduction, regardless of method for measuring PDC. The similarity in results across adherence measures is likely due to the high correlation between them.
Authors: Russel Burge; Bess Dawson-Hughes; Daniel H Solomon; John B Wong; Alison King; Anna Tosteson Journal: J Bone Miner Res Date: 2007-03 Impact factor: 6.741
Authors: Ethel S Siris; Steven T Harris; Clifford J Rosen; Charles E Barr; James N Arvesen; Thomas A Abbott; Stuart Silverman Journal: Mayo Clin Proc Date: 2006-08 Impact factor: 7.616
Authors: S R Cummings; D M Black; D E Thompson; W B Applegate; E Barrett-Connor; T A Musliner; L Palermo; R Prineas; S M Rubin; J C Scott; T Vogt; R Wallace; A J Yates; A Z LaCroix Journal: JAMA Date: 1998 Dec 23-30 Impact factor: 56.272
Authors: M Alan Brookhart; Amanda R Patrick; Colin Dormuth; Jerry Avorn; William Shrank; Suzanne M Cadarette; Daniel H Solomon Journal: Am J Epidemiol Date: 2007-05-15 Impact factor: 4.897
Authors: Daniel H Solomon; Maura D Iversen; Jerry Avorn; Timothy Gleeson; M Alan Brookhart; Amanda R Patrick; Laura Rekedal; William H Shrank; Joyce Lii; Elena Losina; Jeffrey N Katz Journal: Arch Intern Med Date: 2012-02-27
Authors: J T Schousboe; M Gourlay; H A Fink; B C Taylor; E S Orwoll; E Barrett-Connor; L J Melton; S R Cummings; K E Ensrud Journal: Osteoporos Int Date: 2012-02-17 Impact factor: 4.507
Authors: K Ganda; M Puech; J S Chen; R Speerin; J Bleasel; J R Center; J A Eisman; L March; M J Seibel Journal: Osteoporos Int Date: 2012-07-25 Impact factor: 4.507